INSIGHTS ON QUALITY CONTROL

• Building R&D Knowledge Into GMP Documentation

  Integrating R&D knowledge into GMP documentation ensures consistent aseptic powder fill‑finish processes by capturing material insights, defining controls, and enabling reliable, knowledge‑driven manufacturing.

• Why Pharmaceutical Scientists Trust The Discovery Core Rheometer

  Drug formulations demand more than single‑point viscosity data. Explore how rheology reveals stability, flow, and structural behavior across suspensions, topicals, and injectables.

• 0.45 m/s ±20% At Working Position In Closed Sterility Testing Isolators: Requirement Or Convention?

  Balance compliance and efficiency in sterility testing. Explore how a risk-based approach to airflow and isolator technology aligns with Annex 1 while optimizing contamination control.

• The Seamless Path To Market: End-To-End CDMOs As Your Strategic Ally Douglas CDMO

  Partner with an experienced end-to-end CDMO to streamline development, reduce risk, and accelerate your drug’s path to market in today’s complex and competitive pharmaceutical landscape.

• Isokinetic Sampling In Unidirectional Flow

  3/5/2026

  Accurate cleanroom particle monitoring requires precise isokinetic sampling. Understand how to maintain sampling accuracy and meet regulatory airflow requirements for your facility.

• Global Regulatory Harmonization: Comparisons In Aseptic Barrier Systems

  4/20/2026

  Compare global aseptic standards from the FDA, EMA, PIC/S, and WHO. Gain insights into how advanced barrier systems harmonize international requirements to ensure sterile product integrity and safety.

• Ophthalmic Drug Delivery: Meeting Modern Challenges With A Next Generation Solution

  8/17/2026

  Ophthalmic injectable packaging demands early strategic attention. Learn how silicone oil contamination, particulate limits, and dosing accuracy challenges can derail development programs and what it takes to stay compliant.

• Cross-Site Work Within Cambrex's Network

  7/24/2026

  Matthew Zart, Group Leader of Analytical Development, on what happens when a method arrives from another site — inheriting Phase II work from High Point and getting it commercial-ready for the QC lab.

• Revolutionizing The Development, Characterization, And Manufacturing Of Peptides

  7/24/2026

  Erik Feldmann, Technical Director, on the analytical challenges of proteins, peptides, and oligonucleotides — and why he starts every method-development problem by understanding what the customer is trying to achieve.